# Chemed Corp: overview

CHE · NYSE · CIK 19584 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/che.md) · [Financials](/companies/che/financials.md) · [Filings](/companies/che/filings.md) · [Insiders](/companies/che/insiders.md)

Latest reported revenue: [$690.9m](/filings/0000019584-26-000024.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 29, 2026 (XBRL us-gaap:Revenues, accession 0000019584-26-000024).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [411 d](/filings/0001562762-25-000038.md) | [647](/filings/0000019584-26-000012.md) | [619](/filings/0000019584-26-000020.md) | [625](/filings/0000019584-26-000024.md) | [639 d](/filings/0001562762-26-000020.md) | [658](/filings/0000019584-26-000012.md) | [673](/filings/0000019584-26-000020.md) | [691](/filings/0000019584-26-000024.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [27.7% d](/filings/0001562762-26-000020.md) | [14.6%](/filings/0000019584-26-000012.md) | [11.0%](/filings/0000019584-26-000020.md) | [12.0%](/filings/0000019584-26-000024.md) | [15.7% d](/filings/0001562762-26-000020.md) | [12.9%](/filings/0000019584-26-000012.md) | [13.2%](/filings/0000019584-26-000020.md) | [14.0%](/filings/0000019584-26-000024.md) |
| Net margin | % | [22.0% d](/filings/0001562762-26-000020.md) | [11.1%](/filings/0000019584-26-000012.md) | [8.5%](/filings/0000019584-26-000020.md) | [10.3%](/filings/0000019584-26-000024.md) | [12.0% d](/filings/0001562762-26-000020.md) | [10.1%](/filings/0000019584-26-000012.md) | [10.1%](/filings/0000019584-26-000020.md) | [10.4%](/filings/0000019584-26-000024.md) |
| Diluted EPS | $ per share | not reported | [4.86](/filings/0000019584-26-000012.md) | [3.57](/filings/0000019584-26-000020.md) | [4.46](/filings/0000019584-26-000024.md) | not reported | [4.84](/filings/0000019584-26-000012.md) | [5.13](/filings/0000019584-26-000020.md) | [5.45](/filings/0000019584-26-000024.md) |
| Free cash flow | $m | [152 d](/filings/0001562762-26-000020.md) | [19.5](/filings/0000019584-26-000012.md) | [123 d](/filings/0000019584-26-000020.md) | [65.9 d](/filings/0000019584-26-000024.md) | [117 d](/filings/0001562762-26-000020.md) | [71.1](/filings/0000019584-26-000012.md) | [69.3 d](/filings/0000019584-26-000020.md) | [37.9 d](/filings/0000019584-26-000024.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,261](/filings/0001562762-24-000045.md) | [1,202](/filings/0001562762-25-000038.md) | [1,315](/filings/0001562762-25-000038.md) | [1,531](/filings/0001562762-25-000038.md) | [2,530](/filings/0001562762-26-000020.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [27.2%](/filings/0001562762-24-000045.md) | [28.6%](/filings/0001562762-25-000038.md) | [25.9%](/filings/0001562762-26-000020.md) | [23.9%](/filings/0001562762-26-000020.md) | [13.4%](/filings/0001562762-26-000020.md) |
| Net margin | % | [21.3%](/filings/0001562762-24-000045.md) | [20.8%](/filings/0001562762-25-000038.md) | [20.7%](/filings/0001562762-26-000020.md) | [19.7%](/filings/0001562762-26-000020.md) | [10.5%](/filings/0001562762-26-000020.md) |
| Diluted EPS | $ per share | [16.85](/filings/0001562762-24-000045.md) | [16.53](/filings/0001562762-25-000038.md) | [17.93](/filings/0001562762-26-000020.md) | [19.89](/filings/0001562762-26-000020.md) | [18.34](/filings/0001562762-26-000020.md) |
| Free cash flow | $m | [250](/filings/0001562762-24-000045.md) | [253](/filings/0001562762-25-000038.md) | [273](/filings/0001562762-26-000020.md) | [368](/filings/0001562762-26-000020.md) | [325](/filings/0001562762-26-000020.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/che/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $691.3m | 1,484,282 |  | Added +147,592 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $446.2m | 972,474 |  | Added +556,862 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $366.6m | 787,068 |  | Reduced −28,631 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $281.5m | 604,420 |  | Reduced −31,650 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $207.1m | 444,716 |  | Reduced −17,454 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $192.8m | 413,942 |  | Added +2,896 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $185.8m | 403,395 |  | Reduced −97,592 |
| [Boston Partners](/funds/1386060.md) | 2026-06-30 | $130.7m | 280,684 |  | New +280,684 |
| [Epoch Investment Partners, Inc.](/funds/1305841.md) | 2026-06-30 | $124.5m | 267,290 |  | Added +17,167 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $121.3m | 260,561 |  | Added +12,711 |

## Recent filings

[All 1,327 filings](/companies/che/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 09:00 ET | [10-Q](/filings/0000019584-26-000024.md) | Quarterly report, period 2026-09-30 | 0000019584-26-000024 |
| 2026-10-27 | 16:30 ET | [8-K](/filings/0000019584-26-000022.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000019584-26-000022 |
| 2026-07-31 | 09:04 ET | [10-Q](/filings/0000019584-26-000020.md) | Quarterly report, period 2026-06-30 | 0000019584-26-000020 |
| 2026-07-28 | 16:30 ET | [8-K](/filings/0000019584-26-000018.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000019584-26-000018 |
| 2026-05-19 | 10:43 ET | [8-K](/filings/0000019584-26-000014.md) | 5.07 Shareholder vote results | 0000019584-26-000014 |
| 2026-04-28 | 09:00 ET | [10-Q](/filings/0000019584-26-000012.md) | Quarterly report, period 2026-03-31 | 0000019584-26-000012 |
| 2026-04-23 | 16:30 ET | [8-K](/filings/0000019584-26-000010.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000019584-26-000010 |
| 2026-04-13 | 09:03 ET | [8-K](/filings/0000019584-26-000008.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0000019584-26-000008 |
| 2026-04-06 | 09:00 ET | [DEF 14A](/filings/0000019584-26-000005.md) | Proxy statement, period 2025-12-31 | 0000019584-26-000005 |
| 2026-02-27 | 09:36 ET | [10-K](/filings/0001562762-26-000020.md) | Annual report, period 2025-12-31 | 0001562762-26-000020 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001562762-26-000020.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/29f6b949-fa3a-4db3-a17f-92b501243fc6)

## About the filer

- CIK: 19584
- Tickers: CHE
- Exchange: NYSE
- SIC code: 8082 Services-Home Health Care Services
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 09:14 ET. No prices; not investment advice.